Nuvectra Corporation (NVTR) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS
Nuvectra Corporation (NASDAQ:NVTR) released its quarterly earnings results on Tuesday. The company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.07, Briefing.com reports. Nuvectra Corporation had a negative net margin of 286.26% and a negative return on equity of 47.33%. The business had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $5.96 million. During the same period in the previous year, the company earned ($0.85) earnings per share. The firm’s revenue for the quarter was up 188.0% compared to the same quarter last year.
Nuvectra Corporation (NASDAQ:NVTR) traded down 1.15% on Tuesday, reaching $12.03. 37,075 shares of the company traded hands. The company’s market capitalization is $124.41 million. The stock’s 50 day moving average price is $12.60 and its 200 day moving average price is $9.03. Nuvectra Corporation has a one year low of $4.63 and a one year high of $15.00.
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/08/nuvectra-corporation-nvtr-issues-quarterly-earnings-results-beats-estimates-by-0-07-eps.html.
Several research firms recently weighed in on NVTR. B. Riley restated a “buy” rating and set a $12.00 price target on shares of Nuvectra Corporation in a report on Monday, May 15th. Piper Jaffray Companies restated a “neutral” rating and set a $14.00 price target on shares of Nuvectra Corporation in a report on Thursday, July 6th. ValuEngine upgraded shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th. Zacks Investment Research upgraded shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, TheStreet upgraded shares of Nuvectra Corporation from a “d” rating to a “c-” rating in a report on Monday, June 19th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $10.50.
In other news, CEO Scott F. Drees acquired 2,605 shares of Nuvectra Corporation stock in a transaction on Thursday, May 25th. The stock was acquired at an average cost of $9.92 per share, for a total transaction of $25,841.60. Following the purchase, the chief executive officer now owns 90,041 shares in the company, valued at $893,206.72. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Scott F. Drees acquired 7,395 shares of Nuvectra Corporation stock in a transaction on Tuesday, May 30th. The shares were purchased at an average price of $10.41 per share, with a total value of $76,981.95. Following the completion of the purchase, the chief executive officer now owns 99,136 shares in the company, valued at approximately $1,032,005.76. The disclosure for this purchase can be found here.
Nuvectra Corporation Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.